These compounds directly stimulate L-cells to release GLP-1
E.WeigleD
ADVANTAGES & DISADVANTAGES OF TREATMENT OPTIONS CVD: Cardiovascular Death Management of Type 2 Diabetes American Diabetes Assn 2020 Update Based upon recent research findings, the American Diabetes Asson & Europiean Asson for the Study of Diabetes recently updated their consensus treatment recommendations (Buse et al, 2019) for the following subsets of patients with diabetes: High risk diabetic patients GLP-1 agonists & SGLT2 inhibitors to reduce CV & renal risk in high risk patients, without regard to patient HbA1c levels (baseline or target) High risk for atherosclerotic CV disease GLP-1 agonists GLP-1 agonists produce the greatest benefit against CV events Systolic heart failure (HFrEF) & chronic kidney disease (CKD) SGLT2 inhibitors SGLT2 inhibitors have the greatest benefit to prevent progression of CKD, reduce hospitalization for HF, and reduce CV events & CV death Patients with foot ulcers SGLT2 inhibitors a recommended treatment, after consideration of risk vs benefits 2021 ADA Treatment Guidelines Figure 10
Notably, ergothioneine emerged as the plasma metabolite most strongly linked to a decreased risk of coronary disease (p=0.01), cardiovascular mortality (p=0.002), and overall mortality (p=0.0004)
If youve been wondering if IV therapy is right for you, consider these 10 benefits of the treatment: 1
Beyond the Scale: Measuring What Matters What you weigh in on the scale is just a number
